Comparative Pharmacology
Head-to-head clinical analysis: DIPHENOXYLATE HYDROCHLORIDE W ATROPINE SULFATE versus VIBERZI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIPHENOXYLATE HYDROCHLORIDE W ATROPINE SULFATE versus VIBERZI.
DIPHENOXYLATE HYDROCHLORIDE W/ ATROPINE SULFATE vs VIBERZI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diphenoxylate acts as an opioid agonist on mu-opioid receptors in the gastrointestinal tract, reducing peristalsis and increasing intestinal transit time. Atropine sulfate is added at subtherapeutic doses to deter abuse by causing unpleasant anticholinergic effects at high doses.
Guanylate cyclase-C agonist; increases intracellular cyclic guanosine monophosphate (cGMP) leading to activation of cystic fibrosis transmembrane conductance regulator (CFTR) ion channel, resulting in increased intestinal fluid secretion and accelerated transit.
2.5-5 mg (diphenoxylate) orally 4 times daily until diarrhea controlled; maximum 20 mg/day (diphenoxylate).
100 mg orally three times daily with meals.
None Documented
None Documented
Diphenoxylate: terminal half-life of 2.9-5.8 hours (active metabolite difenoxin: 12-14 hours). Atropine: terminal half-life of 2-4 hours. Clinical context: The long half-life of difenoxin contributes to sustained antidiarrheal effect.
Terminal elimination half-life is approximately 8-9 hours, supporting twice-daily dosing.
Diphenoxylate is excreted primarily in feces (via biliary elimination) as the active metabolite difenoxin and its conjugates; approximately 14% is excreted renally as unchanged drug and metabolites. Atropine is excreted renally (30-50% unchanged) and partially in feces.
Primarily fecal (approximately 95% of absorbed dose) with minimal renal excretion (<1%).
Category C
Category C
Antidiarrheal
Antidiarrheal